Join leading experts in the cell and gene therapy sector for a webinar bringing together science, clinical information, and business ethics surrounding the use of mesenchymal stem cells (MSCs) to treat COVID-19. This 75-minute webinar will cover the science and potential therapeutic benefit of MSCs to treat COVID-19; what patients and patient groups should understand about these therapies; and finally, the ethical and safety concerns for companies and clinics promoting therapies outside of a recognized regulatory process or prior to the conclusion of a clinical trial.
Agenda:
Part 1: Science
Daniel Weiss, M.D., Ph.D., Chief Scientific Officer, International Society for Cell & Gene Therapy (ISCT); Professor, University of Vermont School of Medicine
Part 2: Clinical Perspective
Carolyn Hendrickson, M.D., M.P.H., Assistant Professor, Medicine, UC San Francisco
Michael Matthay, M.D., Professor of Medicine, UC San Francisco
Part 3: Ethics and Business Practices
Laertis Ikonomou, Ph.D., Chair, ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell & Gene Therapy; Associate Professor, University at Buffalo, The State University of New York
Mike Lehmicke, Director, Scientific & Industry Affairs, Alliance for Regenerative Medicine (ARM)
Patricia Zettler, J.D., Assistant Professor of Law, The Ohio State University Moritz College of Law
